Clene (CLNN)
(Delayed Data from NSDQ)
$0.35 USD
0.00 (0.78%)
Updated May 24, 2024 04:00 PM ET
After-Market: $0.35 0.00 (-0.28%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Clene Inc. [CLNN]
Reports for Purchase
Showing records 41 - 60 ( 92 total )
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Updates Visual System Data for Phase 2 VISIONARY-MS Trial at 2023 ACTRIMS
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Seeing Is Believing; New VISIONARY-MS Data Endorse CNMAu8 Treatment For Cognitive and Functional Decline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
New MRI Data Support CNM-Au8 Treatment For Brain Neuronal Structural Integrity; Phase 3 Coming
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
CNM-Au8 Improves Neuronal Structural Integrity Over DMT - Phase 3 Planned
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Treating Neurodegeneration With Energy, BIIB''s March AdCom a Big Wildcard
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Treating Neurodegeneration With Energy, BIIB''s March AdCom a Big Wildcard -Transferring Coverage
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Clene Inc.
Industry: Unclassified
CNM-Au8 for Neurodegenerative Diseases Remains Focus as CNM-ZnAg Falters in COVID; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
3Q22 Results; Strategic Partners Are Welcome for CNM-Au8 Programs; COVID-19 Top-Line Data for CNM-ZnAg in 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
New Cash Provides Runway Beyond Needed Answers; Focus on Evolving ALS Clinical Benefit; Target Tweaked to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Company: Clene Inc.
Industry: Unclassified
Important Silver Lining Beyond Negative Headline as ALS to Push Forward
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Clene Inc.
Industry: Unclassified
RESCUE-ALS OLE Continues to Demonstrate CNM-Au8 Survival Benefit; Phase 3 HEALEY-ALS Readout Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J